» Home » Drug Database » isoflurophate
ADVERTISEMENT
ADVERTISEMENT
» Home » Drug Database » isoflurophate
Brand Name :
Floropryl, Diflupyl
Synonyms :
diisopropoxyphosphoryl fluoride, diisopropyl fluorophosphate
Class :
Cholinergic agents
Actions and Spectrum:
Action
Acetylcholinesterase Inhibition: isoflurophate acts as an irreversible inhibitor of acetylcholinesterase. It forms a covalent bond with the enzyme, which prevents it from effectively breaking down acetylcholine. This leads to an increase in the levels of acetylcholine in the synaptic cleft.
Spectrum
Ocular Effects: isoflurophate has been used in the treatment of glaucoma. It reduces intraocular pressure by constricting the pupils and increasing the drainage of aqueous humor, ultimately leading to a decrease in intraocular pressure.
No drug interaction found for isoflurophate and .
may have an increased constipating effect when combined with clozapine
may have an increased anticholinergic effect when combined with glycopyrrolate
zolpidem: they may decrease the therapeutic effect of anticholinesterases
may have an increased anticholinergic effect when combined with cimetropium
may have an increased constipating effect when combined with eluxadoline
may have an increased anticholinergic effect when combined with anticholinergic agents
may increase the anticholinergic effect of Anticholinergic Agents
anticholinergic agents increase the ulcer-producing effect of potassium citrate
may increase the anticholinergic effect of each other when combined
may have an increased anticholinergic effect when combined with anticholinergic agents
levosalbutamol: they may decrease the therapeutic effect of anticholinesterases
oxatomide: they may increase the anticholinesterase effect of anticholinesterases
may increase the effect of beta-blockers
may increase the effect of beta-blockers
may increase the effect of beta-blockers
may increase the effect of beta-blockers
may increase the effect of beta-blockers
may increase the effect of antipsychotic agents
may increase the effect of antipsychotic agents
may increase the effect of antipsychotic agents
may increase the effect of antipsychotic agents
may increase the effect of antipsychotic agents
may increase the effect of antipsychotic agents
may increase the effect of antipsychotic agents
may increase the effect of antipsychotic agents
may increase the effect of antipsychotic agents
may increase the effect of antipsychotic agents
may increase the effect of antipsychotic agents
may increase the effect of antipsychotic agents
may increase the effect of antipsychotic agents
may increase the effect of antipsychotic agents
may increase the effect of antipsychotic agents
may increase the effect of antipsychotic agents
may increase the effect of antipsychotic agents
may increase the effect of antipsychotic agents
may increase the effect of antipsychotic agents
may increase the effect of antipsychotic agents
may increase the effect of antipsychotic agents
may increase the effect of antipsychotic agents
may increase the effect of antipsychotic agents
reduce the therapeutic effect
reduce the therapeutic effect
reduce the therapeutic effect
reduce the therapeutic effect
reduce the therapeutic effect
may increase the neurotoxic effect
may increase the neurotoxic effect
may increase the neurotoxic effect
may increase the neurotoxic effect
may increase the neurotoxic effect
may increase the neurotoxic effect
may increase the neurotoxic effect
may increase the neurotoxic effect
may increase the neurotoxic effect
may increase the neurotoxic effect
may increase the neurotoxic effect
may increase the neurotoxic effect
may increase the neurotoxic effect
may increase the neurotoxic effect
may increase the neurotoxic effect
may increase the neurotoxic effect
may increase the neurotoxic effect
may increase the neurotoxic effect
may increase the neurotoxic effect
may increase the neurotoxic effect
may increase the neurotoxic effect
may increase the neurotoxic effect
may increase the neurotoxic effect
may increase the neurotoxic effect
may increase the neurotoxic (central) effect
may increase the neurotoxic (central) effect
may increase the neurotoxic (central) effect
may increase the neurotoxic (central) effect
may increase the neurotoxic effect
may increase the neurotoxic effect
may increase the neurotoxic effect
may increase the neurotoxic effect
may increase the bradycardic effect
may increase the bradycardic effect
may increase the bradycardic effect
may increase the bradycardic effect
may increase the bradycardic effect
may increase the bradycardic effect
may increase the bradycardic effect
may increase the bradycardic effect
may increase the bradycardic effect
may increase the bradycardic effect
they decrease the efficacy of gastrointestinal agents
they decrease the efficacy of gastrointestinal agents
they decrease the efficacy of gastrointestinal agents
they decrease the efficacy of gastrointestinal agents
they decrease the efficacy of gastrointestinal agents
may increase the risk of adverse effect
may increase the risk of adverse effect
may increase the risk of adverse effect
may increase the risk of adverse effect
may increase the risk of adverse effect
may enhance the adverse/toxic effect
may enhance the adverse/toxic effect
may enhance the adverse/toxic effect
may enhance the adverse/toxic effect
may enhance the adverse/toxic effect
may enhance the adverse/toxic effect
may enhance the adverse/toxic effect
may enhance the adverse/toxic effect
may enhance the adverse/toxic effect
may enhance the adverse/toxic effect
may enhance the adverse/toxic effect
may enhance the adverse/toxic effect
may enhance the adverse/toxic effect
may enhance the adverse/toxic effect
may enhance the adverse/toxic effect
may enhance the adverse/toxic effect
may enhance the adverse/toxic effect
may enhance the adverse/toxic effect
may enhance the adverse/toxic effect
may enhance the adverse/toxic effect
may enhance the adverse/toxic effect
may enhance the adverse/toxic effect
may enhance the adverse/toxic effect
may enhance the adverse/toxic effect
may enhance the adverse/toxic effect
may have an increasingly adverse effect when combined with other anticholinergic agents
may have an increasingly adverse effect when combined with other anticholinergic agents
may have an increasingly adverse effect when combined with other anticholinergic agents
may have an increasingly adverse effect when combined with other anticholinergic agents
may have an increasingly adverse effect when combined with other anticholinergic agents
spironolactone and hydrochlorothiazide
it increases the concentration of thiazide and its diuretics in the serum
it increases the concentration of thiazide and its diuretics in the serum
it increases the concentration of thiazide and its diuretics in the serum
it increases the concentration of thiazide and its diuretics in the serum
it increases the concentration of thiazide and its diuretics in the serum
may decrease the therapeutic effect when combined with anticholinergic agents
may decrease the therapeutic effect when combined with anticholinergic agents
may have an increased tachycardic effect when combined with cannabinoid products
may have an increased tachycardic effect when combined with cannabinoid products
may have an increasingly adverse effect when combined with opioid agonists
may have an increasingly adverse effect when combined with opioid agonists
may have an increasingly adverse effect when combined with opioid agonists
may have an increasingly adverse effect when combined with opioid agonists
anticholinestereses: they may increase the toxic effect of mu-opioid receptor agonists
anticholinestereses: they may increase the toxic effect of mu-opioid receptor agonists
may have an increasingly adverse effect when combined with other anticholinergic agents
may decrease the therapeutic effect when combined with gastrointestinal agents
may decrease the therapeutic effect when combined with gastrointestinal agents
may have an increasingly adverse effect when combined with opioid agonists
may have an increasingly adverse effect when combined with opioid agonists
may have an increasingly adverse effect when combined with opioid agonists
may have an increasingly adverse effect when combined with opioid agonists
may have an increasingly adverse effect when combined with opioid agonists
may enhance the concentration of serum when combined with thiazide diuretics
may enhance the concentration of serum when combined with thiazide diuretics
may have a decreased therapeutic effect when combined with anticholinergic agents
may decrease the therapeutic effect when combined with anticholinergic agents
may decrease the therapeutic effect when combined with anticholinergic agents
may enhance the risk of adverse effect of acetylcholinesterase inhibitors
may enhance the risk of adverse effect of acetylcholinesterase inhibitors
may enhance the risk of adverse effect of acetylcholinesterase inhibitors
may enhance the risk of adverse effect of acetylcholinesterase inhibitors
may enhance the risk of adverse effect of acetylcholinesterase inhibitors
may enhance the risk of adverse effect of acetylcholinesterase inhibitors
may enhance the risk of adverse effect of acetylcholinesterase inhibitors
may enhance the risk of adverse effect of acetylcholinesterase inhibitors
may enhance the risk of adverse effect of acetylcholinesterase inhibitors
may enhance the risk of adverse effect of acetylcholinesterase inhibitors
may enhance the risk of adverse effect of acetylcholinesterase inhibitors
may enhance the risk of adverse effect of acetylcholinesterase inhibitors
may enhance the risk of adverse effect of acetylcholinesterase inhibitors
may enhance the risk of adverse effect of acetylcholinesterase inhibitors
may enhance the risk of adverse effect of acetylcholinesterase inhibitors
may enhance the risk of adverse effect of acetylcholinesterase inhibitors
may enhance the risk of adverse effect of acetylcholinesterase inhibitors
may enhance the risk of adverse effect of acetylcholinesterase inhibitors
may enhance the risk of adverse effect of acetylcholinesterase inhibitors
may enhance the risk of adverse effect of acetylcholinesterase inhibitors
may enhance the risk of adverse effect of acetylcholinesterase inhibitors
may enhance the risk of adverse effect of acetylcholinesterase inhibitors
may enhance the risk of adverse effect of acetylcholinesterase inhibitors
may enhance the risk of adverse effect of acetylcholinesterase inhibitors
may enhance the risk of adverse effect of acetylcholinesterase inhibitors
may enhance the risk of adverse effect of acetylcholinesterase inhibitors
may have an increased anticholinergic effect when combined with anticholinergic agents
may enhance the anticholinergic effect of Anticholinergic agents
may increase the anticholinergic effect of anticholinergic agents
may increase the toxic effect of other Anticholinergic Agents
may decrease the therapeutic effect of Anticholinergic Agents
may diminish the absorption when combined with nitroglycerin
may have an increasingly adverse effect when combined with glucagon
anticholinergic agents increase the toxicity of topiramate
may increases the adverse effect of Opioid Agonists
buprenorphine,long-acting injection
may increases the adverse effect of Opioid Agonists.
acetaminophen/doxylamine/dextromethorphan
may increase the adverse effect of other Anticholinergic Agents
may enhance the adverse/toxic effect
may enhance the adverse/toxic effect
may enhance the adverse/toxic effect
may enhance the adverse/toxic effect
may enhance the adverse/toxic effect
may enhance the adverse/toxic effect
may enhance the adverse/toxic effect
may enhance the adverse/toxic effect
may enhance the adverse/toxic effect
may enhance the adverse/toxic effect
may enhance the risk of adverse effect
may enhance the risk of adverse effect
may enhance the risk of adverse effect
may enhance the risk of adverse effect
may enhance the risk of adverse effect
may enhance the risk of adverse effect
may enhance the risk of adverse effect
may enhance the risk of adverse effect
may enhance the risk of adverse effect
may enhance the risk of adverse effect
may have an increasingly adverse effect when combined with other anticholinergic agents
may have an increasingly adverse effect when combined with other anticholinergic agents
may have an increasingly adverse effect when combined with other anticholinergic agents
may have an increasingly adverse effect when combined with other anticholinergic agents
may have an increasingly adverse effect when combined with other anticholinergic agents
may diminish the therapeutic effect of Acetylcholinesterase Inhibitors
may decrease the therapeutic effect of Acetylcholinesterase Inhibitors
may decrease the therapeutic effect of Acetylcholinesterase Inhibitors
It may enhance the risk of adverse effects when combined with coronary vasodilators
It may enhance the risk of adverse effects when combined with coronary vasodilators
may decrease the therapeutic effect when combined with anticholinergic agents
may have an increasingly adverse effect when combined with other anticholinergic agents
may have an increased tachycardic effect when combined with cannabinoid products
may have an increased tachycardic effect when combined with cannabinoid products
When amantadine is used together with isoflurophate, this leads to a reduction in the therapeutic effectiveness of amantadine
When amitriptyline is used together with isoflurophate, this leads to a reduction in the therapeutic effectiveness of amitriptyline
When amobarbital is used together with isoflurophate, this leads to a reduction in the therapeutic effectiveness of amobarbital
When amoxapine is used together with isoflurophate, this leads to a reduction in the therapeutic effectiveness of amoxapine
When aripiprazole is used together with isoflurophate, this leads to a reduction in the therapeutic effectiveness of aripiprazole
When atracurium is used together with isoflurophate, this leads to a reduction in the therapeutic effectiveness of atracurium
When atropine is used together with isoflurophate, this leads to a reduction in the therapeutic effectiveness of atropine
may enhance the serum concentration of anticholinergic agents
may enhance the serum concentration of anticholinergic agents
anticholinergic agents decrease the efficacy of secretin
It is recommended to apply a fine strip of 0.025% ointment topically roughly (0.5 cm area) one time every 3 days thrice daily
Not indicated
Refer adult dosing
Frequency not defined
unusual tiredness or weakness
sweating
seizures
pounding in the ears
headache
Blurred vision
Black Box Warning:
None
Contraindication/Caution:
Hypersensitivity: isoflurophate should not be used in individuals who have a known hypersensitivity or allergy to the active ingredient or any components of the product.
Asthma: Individuals who have a history of asthma or other respiratory disease could face an elevated risk of experiencing bronchoconstriction or worsening of their respiratory issues when they meet isoflurophate. Hence, it is typically not recommended for such patients.
Cardiovascular Disease: Patients with pre-existing cardiovascular diseases should use isoflurophate with caution, or it may be contraindicated depending on the severity of their condition.
Gastrointestinal Disorders: Individuals with a history of gastrointestinal disorders, such as ulcers or bleeding, may be at increased risk of experiencing gastrointestinal irritation when using isoflurophate.
Pregnancy warnings:
Pregnancy category: N/A
Lactation: Excreted into human milk is unknown
Pregnancy Categories:
Category A: Studies that were well-controlled and met expectations revealed no risk to the fetus in either the first or second trimester.
<b>Category B: There were a lack of studies on pregnant women and no evidence of risk to the fetus in animal experiments.
Category C: there was evidence of risk of adverse effects in animal reproduction studies, and no adequate evidence in human studies must take care of potential risks in pregnant women.
Category D: adequate data with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits.
Category X: Drugs listed in this category outweigh the risks over benefits. Hence these categories of drugs need to be avoided by pregnant women.
Category N: There is no data available for the drug under this category
Pharmacology: It is an irreversible acetylcholinesterase inhibitor.
Pharmacodynamics:
isoflurophate works by forming a covalent bond with acetylcholinesterase, which prevents the enzyme from breaking down acetylcholine.
This leads to an accumulation of acetylcholine in the synaptic cleft and prolongs the action of acetylcholine at cholinergic receptors.
Pharmacokinetics:
N/A
Administration:
The route of administration is ocular.
isoflurophate should be administered by a qualified ophthalmologist or healthcare professional
Patient information leaflet
Generic Name: isoflurophate
Why do we use isoflurophate?
isoflurophate is used to lower intraocular pressure in cases of open-angle glaucoma.
Sometimes, isoflurophate is used both before and after specific eye surgeries, such cataract surgery. It can help to prevent or manage intraoperative and postoperative increases in intraocular pressure.
isoflurophate can be used to induce pupil dilation for certain diagnostic procedures, such as fundus examination or retinal photography.
ADVERTISEMENT
» Home » Drug Database » isoflurophate
Brand Name :
Floropryl, Diflupyl
Synonyms :
diisopropoxyphosphoryl fluoride, diisopropyl fluorophosphate
Class :
Cholinergic agents
It is recommended to apply a fine strip of 0.025% ointment topically roughly (0.5 cm area) one time every 3 days thrice daily
Not indicated
Refer adult dosing
No Drug Intearction Found. for isoflurophate and .